Research Tools Sample Clauses

Research Tools. (a) During each Research Term, each Party or its designee (the “Research Tool Disclosing Party”) may transfer to the other Party or its designee (the “Research Tool Receiving Party”) certain control molecules, recombinant proteins, cell lines, assays or other research related Materials (“Research Tools”) as necessary for the Research Tool Receiving Party to perform its assigned activities under each Research Program as expressly set forth in each Research Plan.
AutoNDA by SimpleDocs
Research Tools. In the event that Sponsor exercises its option to obtain a non-exclusive license to Research Tools under Section 3.1b herein above and elects not to pursue patent protection on such Research Tools, TSRI and Sponsor shall have sixty (60) days from the date of exercise of option by Sponsor in which to execute a license agreement to such Research Tools. This shall in no way restrict TSRI’s right to obtain patent protection on such Research Tools.
Research Tools. HFS may provide some general research tools and third party-provided information for your use. Although HFS attempts to identify the sources of all of the information and other material provided to you and HFS believes that those sources are reliable, we do not check for accuracy. NONE OF THESE TOOLS OR INFORMATION ARE CUSTOMIZED FOR YOU, and HFS is not making individualized recommendations about the suitability of purchases or sales of any of the securities or investment strategies that may be listed, analyzed, referenced or identified in the use of the tools or information. HFS investment representatives may be contacted directly to assist you in learning how to properly use the research tools available through HFS. However, those representatives will not advise you about the suitability of any particular security, transaction, investment or strategy in light of your particular financial circumstances and investment objectives even where the representative may know them.
Research Tools. AFS may provide some general research tools and third party-provided information for your use. Although AFS attempts to identify the sources of all of the information and other material provided to you and AFS believes that those sources are reliable, we do not check for accuracy. NONE OF THESE TOOLS OR INFORMATION ARE CUSTOMIZED FOR YOU, and AFS is not making individualized recommendations about the suitability of purchases or sales of any of the securities or investment strategies that may be listed, analyzed, referenced or identified in the use of the tools or information. AFS investment representatives may be contacted directly to assist you in learning how to properly use the research tools available through AFS. However, those representatives will not advise you about the suitability of any particular security, transaction, investment or strategy in light of your particular financial circumstances and investment objectives even where the representative may know them. Idle Account Funds. Unless otherwise directed by you, all idle funds held within your account will automatically be invested (“swept”) into the Alight Money Market Fund. If you wish to invest the funds held in Alight Money Market Fund shares into other securities, it is your responsibility to monitor available balances in the shares and to direct AFS personnel to make the appropriate transactions, subject to the restrictions placed on the account by the fiduciaries. All pertinent information, including statements about investment policies, risks, considerations, charges, and expenses, pertaining to the Alight Money Market Fund can be found in the Alight Money Market Fund prospectus, as it may be amended from time to time. A free copy of this prospectus is available by contacting an AFS representative or by visiting xxx.xxxxxxxxxxxxxxxxxxxxxxxx.xxx. Please note that AFS and AFS’ parent company, Alight Solutions LLC (“Alight Solutions”), each receive compensation for the services that they provide, respectively, to the Alight Money Market Fund. These arrangements are described thoroughly in the prospectus. Neither AFS nor Alight Solutions are banks, and shares of the Alight Money Market Fund are not obligations of, or endorsed or guaranteed by, any bank or other depository institution, nor are they insured by the Federal Deposit Insurance Corporation (FDIC), the Federal Reserve Board, or any government agency. Although the Alight Money Market Fund seeks to preserve the value of your invest...
Research Tools. Guidance Note for section 5 of Schedule 3: This section is not intended to be exhaustive, but allows the parties to specify their Materials/ Research Tools for clarity. No rights are granted to the parties in relation to the Research Tools (as Research Tools are excluded from the definition of Pre-existing IPR). Contributing Party Description Use in the Project Guidance Note for section 5.2 of Schedule 3: Each party provides a licence to the other parties to Use its Pre-existing IPR (see clause 9.2). If a party wants to impose restrictions on the other parties' Use of its Pre-existing IPR, the restrictions should be set out in this section. If the Pre-existing IPR is likely to be incorporated into the Project IP or be used by a party as part of its role in the Project, any restrictions should be carefully considered to avoid restricting a party in using the Project IP or undertaking the Project.
Research Tools. The parties acknowledge that the SMA research and clinical communities will benefit from the availability of Research Tools. Company agrees to use commercially reasonable efforts to make Research Tools Controlled by it available to members of the spinal muscular atrophy research and clinical communities (excluding for-profit entities engaged in pharmaceutical research and development) for research or educational purposes on commercially reasonable terms as promptly as practicable following request by the Foundation or such person (it being understood that neither Company nor its corporate partners shall charge reach-through royalties with respect to drugs discovered by such persons using Research Tools, so long as such drugs themselves are not covered by Company Technology); provided, however, that Company shall not have any obligation to provide such access before the publication of patent applications containing claims (adequately supported by written description) that cover the relevant Research Tool. Notwithstanding the foregoing, if Company believes in good faith that [**], then Company shall so notify the Foundation in writing, and the parties shall discuss in good faith how to proceed. ​
Research Tools 
AutoNDA by SimpleDocs

Related to Research Tools

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

  • Licensed Technology The term “Licensed Technology” shall mean the Licensed Patent Rights, Licensed Know-How and Licensed Biological Materials.

  • Licensed Materials The materials that are the subject of this Agreement are set forth in Appendix A ("Licensed Materials").

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Licensed Software Computer program(s) provided by Contractor in connection with the Deliverables, subject to Section 14 of this Contract.

  • Research Program 2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A which is hereby incorporated in full by reference (“Research Program”), and will furnish the facilities necessary to carry out said Research Program. The Research Program will be under the direction of _____________________ (“Principal Investigator”), or his or her successor as mutually agreed to by the Parties and will be con­ducted by the Principal Investigator at the University.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Third Party Technology Customer is hereby notified that third parties have licensed certain technology to Company, which is contained in the Software. Notwithstanding anything herein to the contrary, Customer hereby consents to the disclosure of Customer’s identity, and such other terms of this Agreement as necessary, to such third party licensors for the purpose of enabling Company to comply with the terms and conditions of such third party licenses. Any such Customer information will be provided pursuant to an obligation of confidentiality and nondisclosure at least as stringent as that imposed by this Agreement.

  • Technology Discoveries, innovations, Know-How and inventions, whether patentable or not, including computer software, recognized under U.S. law as intellectual creations to which rights of ownership accrue, including, but not limited to, patents, trade secrets, maskworks and copyrights developed under this Agreement.

  • Background Technology List here prior contracts to assign Inventions that are now in existence between any other person or entity and you. [ ] List here previous Inventions which you desire to have specifically excluded from the operation of this Agreement. Continue on reverse side if necessary.

Time is Money Join Law Insider Premium to draft better contracts faster.